Lupin's ANDA201446 for Levonorgestrel Receives FDA AP Status
Lupin's ANDA201446 for Levonorgestrel has been granted Abbreviated Approval (AP) status by the FDA.
Asset / Drug
Drug and asset intelligence for Levonorgestrel with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Lupin Ltd's ANDA091440 for a combination of Levonorgestrel and Ethinyl Estradiol has received an Abbreviated Approval (AP) status.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.